El medicamento ZYPREXA VELOTAB 15 mg COMPRIMIDOS BUCODISPERSABLES con los principios activos OLANZAPINA tiene la siguiente información en la sección 4.8
Resumen del perfil de seguridad

*Adultos*

![](data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAAPAe0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Y8FNMviP4gWj3l3cQ2/iACBbm5kn8lX0+zmZELklU3yOQgwq7sAAcV2dUrPS7DT7zUruzg8qbU7gXV025j5koijhDYJwPkijGBgfLnqSTdoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAoDWtHOunQRq1mdXEP2g2Hnp54izjzPLzu254zjFSW+qaZdXslja6jaz3UUazSQRzKzojEhWKg5AJVgD0O0+lcD4f0TWB4kn0/wAS+Gbq4TT9au9W0zXE1BTblZWkKL5YkEiyLHcPDtMZQhc7uQKreBPCOtaH/wAK7F3pS2i6R4bvLC+CyRnyriSSyYL8rHdu8mU5GRkcnkUAeg3Os2djcvFqG+zjGNtzMuIXyP7/AEXnjDYJPQHitGuQ1zVdJ/tWfT9W8Rz2sCbQbS0jkiZsrn55Vyx6gjYU9Dmt/Q/7J/sKzTQYYodMjj8q3jhj8tERfl2quBgDGOlAGB/wnEP/AAmx8PNYEQ/2l/Y63HmfMbr7D9u+5tx5fk5G7dncMbcfNXR6bqEep2pvLcA2rsfIlByJkH8Y4+6TnBGQy4YHBrM1TQob7VIWhsYYfOJa7vVjTzGQBV8oE8guMKWwfkVgCCVI8j+Ifh349XDWzfD7WEtbo3t9JezTXK+VNA0oNmsaNnZsh+RsKuWBPzZ3EA//2Q==)Las reacciones notificadas más frecuentemente (observadas              de los pacientes) asociadas al uso de olanzapina en ensayos clínicos fueron somnolencia, aumento de peso, eosinofilia, aumento de los niveles de prolactina, colesterol, glucosa y triglicéridos (ver sección 4.4), glucosuria, aumento del apetito, mareos, acatisia, parkinsonismo, leucopenia, neutropenia (ver sección 4.4), discinesia, hipotensión ortostática, efectos anticolinérgicos, aumentos asintomáticos y transitorios de las aminotransferasas hepáticas (ver sección 4.4), exantema, astenia, cansancio, fiebre, artralgia, aumento de la fosfatasa alcalina, gamma glutamil transferasa alta, ácido úrico alto, creatinfosfoquinasa alta y edema.

Tabla de reacciones adversas

![](data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAAJAAgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6XsRefa4f+ENFzHpnmL5v9oBvsfl7l3eQrfvQdn+rCYgx0orw2z/4/wC3/wCui/zooA//2Q==) ![](data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAAJAAgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6XsRefa4f+ENFzHpnmL5v9oBvsfl7l3eQrfvQdn+rCYgx0orw2z/4/wC3/wCui/zooA//2Q==) ![](data:image/jpg;base64,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)La siguiente tabla recoge las reacciones adversas y las exploraciones complementarias observadas durante la experiencia postcomercialización y en los ensayos clínicos. Las reacciones adversas se enumeran en orden decreciente de gravedad dentro de cada intervalo de frecuencia. Los intervalos de frecuencia utilizados son: Muy frecuentes ( 1/10), frecuentes ( 1/100 a 1/10), poco frecuentes

![](data:image/jpg;base64,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) ![](data:image/jpg;base64,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) ![](data:image/jpg;base64,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) ![](data:image/jpg;base64,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) ![](data:image/jpg;base64,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)( 1/1.000 a 1/100), raras ( 1/10.000 a 1/1.000), muy raras ( 1/10.000), frecuencia no conocida (no puede estimarse a partir de los datos disponibles).

 **Muy frecuentes**  **Frecuentes**  **Poco frecuentes**  **Raras**  **Frecuencia**

          **no conocida** 
          
 **Trastornos de la sangre y del sistema linfático**   
   Eosinofilia

          Leucopenia10 Neutropenia10    Trombocitopenia11   
 **Trastornos del sistema inmunológico**   
     Hipersensibilidad11     
 **Trastornos del metabolismo y de la nutrición**   
 Aumento de peso1  Niveles de colesterol elevados2,3

          Niveles de glucosa elevados4

          Niveles de triglicéridos elevados2,5 Glucosuria Aumento del apetito  Aparición o exacerbación de diabetes ocasionalmente asociada a cetoacidosis o coma, incluyendo algún caso mortal (ver sección 4.4)11  Hipotermia12   
 **Trastornos del sistema nervioso**   
 Somnolencia  Mareos

          Acatisia6  Convulsiones, en la

          mayoría de los  Síndrome neuroléptico

          maligno (ver sección   

     Parkinsonismo6 Discinesia6  casos existían antecedentes de convulsiones o factores de riesgo de convulsiones11

           

          Distonía (incluyendo crisis oculógiras) 11 Discinesia tardía11 Amnesia9 Disartria Tartamudeo11

          Síndrome de piernas inquietas11  4.4)12

          Síntomas de retirada7,

          12   
          
 **Trastornos cardiacos**   
     Bradicardia Prolongación del

          intervalo QTc (ver sección 4.4)  Taquicardia/fibrilación ventricular, muerte súbita (ver sección

          4.4)11   
 **Trastornos vasculares**   
 Hipotensión ortostática10    Tromboembolismo (incluyendo tromboembolia pulmonar y trombosis venosa

          profunda) (ver sección 4.4)     
 **Trastornos respiratorios, torácicos y mediastínicos**   
     Epistaxis9     
 **Trastornos gastrointestinales**   
   Efectos anticolinérgicos transitorios leves, incluyendo estreñimiento y

          sequedad de boca  Distensión abdominal9 Hipersecreción salival11  Pancreatitis11   
 **Trastornos hepatobiliares**   
   Aumentos asintomáticos y transitorios de las aminotransferasas hepáticas (ALT, AST) especialmente al comienzo del

          tratamiento (ver sección 4.4.)    Hepatitis (incluyendo daño hepatocelular, colestásico o mixto)11   
 **Trastornos de la piel y del tejido subcutáneo**   
   Exantema  Reacciones de fotosensibilidad Alopecia    Reacción a fármaco con eosinofilia y síntomas sistémicos (DRESS

          por sus siglas en 

           inglés) 
          
 **Trastornos musculoesqueléticos y del tejido conjuntivo**   
   Artralgia9    Rabdomiolisis11   
 **Trastornos renales y urinarios**   
     Incontinencia urinaria, retención urinaria Dificultad para

          iniciar la micción11     
 **Embarazo, puerperio y enfermedades perinatales**   
         Síndrome de abstinencia neonatal al fármaco (ver sección

          4.6) 
 **Trastornos del aparato reproductor y de la mama**   
   Disfunción eréctil en hombres Disminución de la libido en hombres y mujeres  Amenorrea Agrandamiento de las mamas Galactorrea en mujeres Ginecomastia o agrandamiento de las mamas en

          hombres  Priapismo12   
 **Trastornos generales y alteraciones en el lugar de administración**   
   Astenia Cansancio Edema

          Fiebre10       
 **Exploraciones complementarias**   
 Aumento de los niveles plasmáticos de prolactina8  Aumento de la fosfatasa alcalina10 Niveles elevados de creatinfosfoquinasa11 Gamma glutamil transferasa alta10

          Ácido úrico elevado10  Aumento de la bilirrubina total     

![](data:image/jpg;base64,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)1 Se observó un aumento de peso clínicamente significativo en los niveles basales de todas las categorias de índice de masa corporal (IMC). Después del tratamiento a corto plazo (duración media de 47 días), se

15% del mismo y de forma poco frecuente (0,8%)

. Se observó de forma muy frecuente un aumento              15% y              del nivel basal del peso corporal (64,4%, 31,7% y 12,3% respectivamente) en pacientes con una exposición a largo plazo (al menos 48 semanas).

2 El aumento medio de los valores de lípidos en ayunas (colesterol total, colesterol LDL y triglicéridos) fue mayor en pacientes sin evidencia de desajustes lipídicos basales.

![](data:image/jpg;base64,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)3 Observados para niveles basales normales en ayunas (<5,17 mmol/l) que aumentaron a niveles elevados ![](data:image/jpg;base64,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) mmol/l). Fueron muy frecuentes los cambios en los niveles de colesterol en ayunas desde niveles basales límites              - <6,2 mmol/l) a niveles elevados ![](data:image/jpg;base64,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) mmol/l).

![](data:image/jpg;base64,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)4 Observados para niveles basales normales en ayunas (<5,56 mmol/l) que aumentaron a niveles mmol/l). Fueron muy frecuentes los cambios en los niveles de glucosa en ayunas desde

- <7 mmol/l![](data:image/jpg;base64,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) mmol/l).

![](data:image/jpg;base64,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)5 Observados para niveles basales normales en ayunas (<1,69 mmol/l) que aumentaron a niveles elevados              mmol/l). Fueron muy frecuentes los cambios en los niveles de triglicéridos en ayunas

mmol/l - <2,26 ![](data:image/jpg;base64,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) mmol/l).

6 En ensayos clínicos la incidencia de parkinsonismo y distonía en pacientes tratados con olanzapina fue numéricamente mayor pero sin diferencia estadísticamente significativa de la de placebo. Los pacientes tratados con olanzapina presentaron una menor incidencia de parkinsonismo, acatisia y distonía en comparación con dosis correspondientes de haloperidol. En ausencia de información detallada de antecedentes individuales sobre alteraciones del movimiento de tipo extrapiramidal, agudas y tardías, en la actualidad no se puede llegar a la conclusión de que olanzapina produzca menos discinesia tardía y/u otros síndromes extrapiramidales tardíos.

7 Se han notificado, síntomas agudos tales como sudoración, insomnio, temblor, ansiedad, náuseas y vómitos al interrumpir el tratamiento con olanzapina de forma repentina.

8 En ensayos clínicos de hasta 12 semanas, en aproximadamente un 30% de los pacientes tratados con olanzapina que presentaron valores basales normales de prolactina, las concentraciones plasmáticas de prolactina excedieron el límite superior del rango normal. En la mayoría de estos pacientes, las elevaciones fueron moderadas en términos generales, y se mantuvieron por debajo de dos veces el límite superior del rango normal.

9 Reacciones adversas identificadas en los ensayos clínicos de la Base de Datos Integrados de Olanzapina.

10 Según la evaluación de los valores medidos en los ensayos clínicos de la Base de Datos Integrados de Olanzapina.

11 Reacciones adversas identificadas a partir de notificaciones espontáneas post comercialización con una frecuencia determinada utilizando la Base de Datos Integrados de Olanzapina.

12 Reacciones adversas identificadas a partir de informes espostáneos post comercialización con una frecuencia estimada en el límite superior del intervalo de confianza del 95% utilizando la Base de Datos Integrados de Olanzapina.

Exposición a largo plazo (al menos 48 semanas)

La proporción de pacientes que presentaron un cambio negativo clínicamente significativo en el aumento de peso o en los niveles de glucosa, colesterol total/LDL/HDL o triglicéridos aumentó con el tiempo. En pacientes adultos que completaron de 9 a 12 meses de tratamiento, la tasa media de aumento de los niveles de glucosa sanguínea disminuyó después de aproximadamente 6 meses.

Información adicional en poblaciones especiales

En ensayos clínicos realizados en pacientes de edad avanzada con demencia, el tratamiento con olanzapina se asoció con una mayor incidencia de muertes y reacciones adversas cerebrovasculares en comparación con placebo (ver sección 4.4). Las reacciones adversas muy frecuentes asociadas con el uso de olanzapina en este grupo de pacientes fueron trastornos de la marcha y caídas. Se observaron con frecuencia neumonía, aumento de la temperatura corporal, letargo, eritema, alucinaciones visuales e incontinencia urinaria.

En ensayos clínicos realizados en pacientes con psicosis inducida por fármacos (agonistas dopaminérgicos) asociada a enfermedad de Parkinson, se han notificado de forma muy frecuente casos de empeoramiento de la sintomatología parkinsoniana y alucinaciones, y de forma más frecuente que con placebo.

![](data:image/jpg;base64,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)En un ensayo clínico realizado en pacientes que presentaban manía bipolar, el tratamiento combinado con valproato y olanzapina dio lugar a una incidencia de neutropenia de 4,1%; un posible factor asociado podría ser la presencia de niveles plasmáticos elevados de valproato. La olanzapina administrada junto con litio o valproato, dio lugar a una mayor incidencia ( 10%) de temblor, sequedad de boca, aumento del apetito y aumento de peso. Los trastornos del lenguaje también fueron notificados de forma frecuente. Durante el tratamiento con olanzapina en combinación con litio o divalproex (asociación de ácido valproico y valproato sódico) ![](data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAAOAOgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3+w+J/wBpRLS5hS11mae2tTpk8LxT2cspfO9WIEiDYdsiHa5yBjrXbaFeaxd2Nwda09bK5huJIk2MCs8YPySAZJXIP3SSQQeowazr7wD4U1PTZtP1HTDeQywxQbpp5HkRI23RhJC25SrfMCCDnnNbOm6XaaNpSafp6P5UYODNM8rsfVnclmPuSTQB5vY/EzXX07RNbvdFs/7K1vT7m5gWGVvNhlhiMu18jBVlR+RjBA6542dG8Xa5qlxo2nzwafaXmt2EmrWrLvkWK3RbfKuMrmTfOBwcYGevBXwX4Ag0bwLpej+IIo7q/t7GSylMVzJJEqyH94IywUruGMkAHtXR/wDCL6J9m0qFLQx/2RH5VlIkjCSBNmwqHzuwVABBJzgZ6CgDz+48fah4m8Ja/Y6dbw6fqdhpN3LfLKzMFkSWe32xsCDgvbykP2G35cnhLX4gXmheCL4Cxjum0HwhZa0rPIQZ2ZJQUb0/1HX/AGunFdve+B/DF/LFNNpxSSO2ksy0M0kRkhk5eNyrDeCSThs8knqTUV14A8KXlq1tNpjNC2nDSnjFxKqyWwztjfDfNjc2CckZODzQBi6l4s0/QPGGvhdIhS9MOko10Dg3D3NxLBErnHCowz9GNb+j69eXHi7WfDGpQx/adPht7tLiBSsc0U28D5SSVYNE4IycjB74Gbp/g5r681e/8WWdnI+q2VrYy2UEzzxBYGlZXDuqtuJmz0yNoOSea6qz061sXlkhVjLNjzJZHLu4HQFiScDJwPc+tAHFxePrqSa1jOnRYm8SzaCx3nhUWQiQcdTs6e/WotD8fanqms6BHPp9tFY6zc6jZrsdjJFJaySKGJPBVhG3HUHH4dEfBPhs6l/aH2BvP+3f2kuJ5AiXO0qZFXdtBIJzgc55zUtp4Q8P2MmmyWtiY202aee1PmufLeYsZW5PO4u3XPU4oAzvEGqWun+ONDifSobi7exv5obpjh4RGIiyD2bK5P8As1zdr8UryO1tb7VtNt0tb7QINbt/Jdsxl3jjKSE8YBlQ7h0G7jjn0C+0LS9S1G31C8tzJc20MsETiRl2pKAHHB77Rz7Vnf8ACD+Fvs8ds+kpJBHpv9jrFI7On2Tj90QTgj5Rz1460AZ2ueJfEPh+2X7VY2Fw9zqlpYWkscjIrrOypvZOSu1iR1OQM8dKr2fizxLdzzwW+kWt3Ppd9Dp+pRwNtXc0cbySRu7DCqJQQpUltp5BxWtaeA/DFnpdtp0VlM8FtcRXUZmupZZBJEcxkuzFiFPQE4HpUr+C/Dj+LW8VfYXj1VwolkjnkRJtowpkjDBHYDoWBI49KAOVsvH2vanfaDHa6dYRQazd6hYIZHdmhktmlw5xgMpERyODkjmpNH+IOpa9pOjx2OnQx6zf6fcXzRHMkQMMoiKj5lOGc9ew7GuqtfCHh+zfT2trExnTp57m2/eufLkm3ea3J53b26+pxWfcfDjwfc2Gl2baZJGmlO72ckF1LFLDvOXAkVgxVieVJwfSgDndY+I2u6faazMNBtrabRdNs9Su7eefexEpcSRKycbl8s4bkH09JLfxrqtjr/imDUZIbiOLXrPSNPjWMoI/PhgYFjk5wZGJ9ccYrrLzwb4cvl1FbnTgy6lbRWl0okdRJFHnYnB4A3N0x1om8HeHLifUpp9P8xtTeKW5DSuVeSMKEkAzhXARPmXB+Uc8UAR6Hr11e69ruganAiXOkmFvtEOVjnilQsrAEkqQVcEZPQHPPFS21bUGv4YfD5l12xMgWSa4Xy44lzyVn48zA7BWJPVhXSWmn21ks32dW3zHdJI7F3cgAAknJOAAKqLpmoKwP/CRXpAP3fKgx9P9XQBymo+EdDk+IWlz2Nq8WpBptSubrznc8KUQEFscvJuAxj90RWXpkereD9N1b+2dQEccWnwz3ckLmQwJDEwnuf8AflI+UdflLHOCK9MSyto9Rm1BY/8ASZo0id8k5VCxUe3Lt+dQyaTp0ttf201qs0WobhdLJ8wmDLtIOe23jHTFAFLS9d06fSb2WOOS1TSiYbiGTBaHbGr44JB+RlPBPWvNdR8ZXlv4k8M+NNQ2f2S3hfVdYFrblg2xRayBWycMwU8Ngcs3Hc+rabo+naVazW9nBhJ3MkxkYyNKxAGWZiS3AA57ADtWLZfD/wAJWD2zW+lnZawz28EUk8kkUUM23zIlRmKhDtX5cYGOAKAOU8dav4ik+H/iRLyxWC1+xwT219A+zczSgPFt3FvlG07+AwfoMc9n4w8QzeGtEtr+C1S5kn1CzsQjsVA8+4jh3ZA7b8/hVWx+HnhPTvDlz4dttPl/sy52q8Mt3NJhVOVRSzEqgI4VSAPSl8d+Hb/xN4dtNM09oFePVLG8kM8rx/u4LmOZwCqk7iEIHTk9RQBg2fj3WB4hm8I6pYW0Wurfm1jmtlaSCSL7MLgSBWKndg7Su7qM5xxU1z481LSYdLPijTE0E3IKyXEqtNbCUSmPY0qEiHcNrKX4O7bwQa3NS8B+F9X002OoWDzA3QvvPFxIk6zgbRIJVYOGCgLkH7vHTirkvhfRZrGOxlt5HtEjWIwNPIUlVTkBwTh+Sclsk5Oc0Ac5/wAJ5cNp+m6/DZxzaNe60dGZFU+dETctarNnOCDKq5XAIVic8YJXTW/hvRbS7e5trMRF7lrwxqzeX57fek2Z2hjkknHUk9eaKAP/2Q==) corporal con respecto al nivel basal en el 17,4% de los pacientes, durante la fase aguda del tratamiento (hasta 6 semanas). El tratamiento a largo plazo con olanzapina (hasta 12 meses) para la prevención de las recaídas en pacientes con trastorno bipolar se asoció a un incremento d![](data:image/jpg;base64,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) con respecto al valor basal, en el 39,9% de los pacientes.

Población pediátrica

El uso de olanzapina no está indicado para el tratamiento de niños y adolescentes menores de 18 años. Aunque no se han realizado ensayos clínicos diseñados para comparar adolescentes y adultos, se han comparado los datos de los ensayos clínicos realizados en adolescentes con los de los ensayos clínicos realizados en adultos.

La siguiente tabla resume las reacciones adversas notificadas con mayor frecuencia en pacientes adolescentes (edades comprendidas entre 13 y 17 años) que en pacientes adultos o reacciones adversas que únicamente se han identificado durante los ensayos clínicos a corto plazo en adolescentes. Parece ser que el aumento de peso clínicamente significativo ![](data:image/jpg;base64,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)ayor frecuencia en la población adolescente en comparación con adultos con exposiciones comparables. La magnitud del aumento de peso y la proporción de pacientes adolescentes para los que dicho aumento fue clínicamente significativo, fueron mayores para la exposición a largo plazo (de al menos 24 semanas) que a corto plazo.

![](data:image/jpg;base64,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) ![](data:image/jpg;base64,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) ![](data:image/jpg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/2wBDAAUEBAQEAwUEBAQGBQUGCA0ICAcHCBALDAkNExAUExIQEhIUFx0ZFBYcFhISGiMaHB4fISEhFBkkJyQgJh0gISD/2wBDAQUGBggHCA8ICA8gFRIVICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICD/wAARCAAIAAgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6dH9qQ6nu8UJdXMHnH7O2nBjaKpZ1TzI1/ebijDfv3xAqGBU0UUUAf//Z)Las reacciones adversas se enumeran en orden decreciente de gravedad dentro de cada intervalo de frecuencia. Los intervalos de frecuencia utilizados son: Muy frecuentes ( 1/10), frecuentes ( 1/100 a 1/10).

 **Trastornos del metabolismo y de la nutrición**

          *Muy frecuentes:* Aumento de peso13, niveles de triglicéridos elevados14, aumento del apetito

          *Frecuentes:* Niveles de colesterol elevados15 
  
 **Trastornos del sistema nervioso**

          *Muy frecuentes:* Sedación (incluyendo: hipersomnia, letargia, somnolencia) 
 **Trastornos gastrointestinales**

          *Frecuentes:* Sequedad de boca 
 **Trastornos hepatobiliares**

          *Muy frecuentes:* Aumentos de las aminotransferasas hepáticas (ALT/AST; ver sección 4.4) 
 **Exploraciones complementarias**

          *Muy frecuentes:* Disminución de la bilirrubina total, elevación de la GGT, aumento de los niveles plasmáticos de prolactina16 

![](data:image/jpg;base64,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)13 Después del tratamiento a corto plazo (duración media de 22 días), se observó de forma muy frecuente (40,6%) un aumento del peso corporal (kg) 7% con respecto al valor basal del peso

(de al menos 24 semanas), el 89,4% presentaron una

ga              55,3% presentaron una ganancia del nivel basal del peso corporal.

![](data:image/jpg;base64,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)14 Observados para niveles basales normales en ayunas (<1,016 mmol/l) que aumentaron a niveles elevad              mmol/l) y cambios en los niveles de triglicéridos en ayunas desde niveles basales

mmol/l - <1,467 ![](data:image/jpg;base64,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) mmol/l)

  ![](data:image/jpg;base64,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)15 Se observaron de forma frecuente cambios en los niveles de colesterol total en ayunas desde niveles basales normales (<4,39 mmol/l) que aumentaron a niveles elevados ( 5,17 mmol/l). Fueron muy frecuentes los cambios en los niveles de colesterol total en ayunas desde niveles basales límites ![](data:image/jpg;base64,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)

![](data:image/jpg;base64,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)- <5,17 mmol/l) a niveles elevados              mmol/l).

16 El aumento de los niveles plasmáticos de prolactina fue notificado en el 47,4% de los pacientes adolescentes.

Notificación de sospechas de reacciones adversas

Es importante notificar sospechas de reacciones adversas al medicamento tras su autorización. Ello permite una supervisión continuada de la relación beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del sistema nacional de notificación incluido en el Anexo V.